Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)

The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced targeted treatments, such as Roche’s Polivy and Gazyva, BeiGene’s Brukinsa, InnoCare’s Hibruka, CAR T-cell therapies, and bispecific antibodies. Despite these novel therapies, rituximab (Roche’s MabThera, biosimilars) will maintain its dominance owing to its established position in the treatment paradigm. Growth is further fueled by rising diagnosed incidence, likely due to an aging population and advancements in personalized medicine, which arise from a deeper understanding of the genetic changes underlying NHL. This report evaluates how clinical and nonclinical factors—price dynamics, inclusion in China’s National Reimbursement Drug List (NRDL), and the entry of generics or biosimilars—will influence the launch and uptake of new and existing therapies. Understanding the impact of these intersecting factors will be crucial for the success of key players in this highly competitive market.

QUESTIONS ANSWERED

• What is the size of clinically and commercially relevant drug-treatable NHL population, and how is the disease currently managed?
• What are the key unmet needs in the management of NHL?
• Which are the key future players and what factors are driving growth in the NHL market?
• What are interviewed experts’ insights into new and existing therapies?
• What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?

PRODUCT DESCRIPTION

China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy in China.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.

Release date:

December 2025

Geography:

China

Primary research:

Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 hematologist-oncologists in China

Epidemiology:

Diagnosed incidence of non-Hodgkin’s lymphoma in urban versus rural China, clinically relevant and market-relevant drug-treatable populations.

Forecast:

10-year, annualized, drug-level sales and patient share of key non-Hodgkin’s lymphoma therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions.

Drug treatments

Coverage of key current and late-phase emerging therapies

Custom drug modeler

Integrated tool to input customized forecast assumptions (e.g., launch date, price)